Safety and efficacy of a combination of Paromomycin and Miltefosine for two versus three courses in patients with Post Kala-Azar Dermal Leishmaniasis (PKDL) - an observational pilot Study

PKDL is a dermal form of leishmaniasis caused by protozoal parasite Leishmania donovani. It is characterized by macular, popular and nodular lesions or a mixture of these¹. It is mainly seen in Sudan and India, where it follows treatment of visceral leishmaniasis (VL) in 50% and 5-10% of cases respectively². A phase III study on miltefosine-paromomycin combination for 10 days for treatment of Indian visceral leishmaniasis (n=157) revealed high cure rate (98.7%) with minimal toxicity, good compliance, lesser treatment duration and non-inferiority to standard amphotericin B³. We, therefore, aimed to assess the efficacy and safety of miltefosine plus paromomycin combination in thirty PKDL patients.

This article is protected by copyright. All rights reserved.

http://ift.tt/2dHaLXz